Ilmarinen Mutual Pension Insurance Co Acquires 322,000 Shares of Pfizer Inc. (NYSE:PFE)

Ilmarinen Mutual Pension Insurance Co lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 48.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 982,000 shares of the biopharmaceutical company's stock after purchasing an additional 322,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co's holdings in Pfizer were worth $26,052,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. PSI Advisors LLC lifted its stake in shares of Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after acquiring an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC raised its holdings in Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. raised its holdings in Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares during the last quarter. Lipe & Dalton lifted its position in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 400 shares during the period. Finally, Oliver Luxxe Assets LLC boosted its stake in shares of Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Down 5.4 %

PFE traded down $1.30 during trading on Friday, hitting $22.99. 79,829,399 shares of the company's stock were exchanged, compared to its average volume of 39,460,357. Pfizer Inc. has a fifty-two week low of $22.95 and a fifty-two week high of $31.54. The stock has a market cap of $130.39 billion, a P/E ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. The business's 50 day moving average is $25.87 and its two-hundred day moving average is $26.72. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.